Halozyme Therapeutics, Inc. — 2016 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2016. The filing also reports unaudited fourth-quarter results. Filed February 28, 2017.
Business context
Halozyme is a biotechnology company with two principal activities: developing its oncology pipeline, led by investigational PEGPH20, and licensing its ENHANZE technology, based on recombinant human hyaluronidase (rHuPH20), to drug-company partners. Its marketed proprietary product is Hylenex; it also earns royalties, product-supply revenue, collaboration fees and research reimbursements. Roche and Baxalta were the only partners generating royalties at year-end.
Financial performance and position
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Total revenue | $146.7 million | $135.1 million |
| Product sales, net | $53.4 million | $46.1 million |
| Royalties | $51.0 million | $31.0 million |
| Collaboration-agreement revenue | $42.3 million | $58.0 million |
| Research and development expense | $150.8 million | $93.2 million |
| Operating loss | $83.2 million | $27.5 million |
| Net loss | $103.0 million | $32.2 million |
| Net loss per share, basic and diluted | $0.81 | $0.25 |
| Net cash used in operating activities | $50.4 million | $37.1 million |
Revenue increased 9%, as higher royalties and product sales more than offset lower collaboration revenue, which included substantial prior-year upfront fees from AbbVie and Lilly. Royalties rose 65%, mainly reflecting sales growth for Roche’s Herceptin SC and MabThera SC and Baxalta’s HYQVIA. Product sales rose 16%, principally on increased bulk rHuPH20 sales. R&D expense rose 62%, primarily due to PEGPH20 clinical work and Roche-related manufacturing activity. Interest expense increased to $20.0 million from $5.2 million, largely because of the royalty-backed loan.
Product-sales gross profit was $20.2 million, implying a product-sales gross margin of approximately 37.8%, compared with approximately 36.5% in 2015. This is the margin on product sales, not on total revenue. The company remained loss-making; management reported cumulative net losses of approximately $585.3 million through year-end.
| Balance-sheet and liquidity metric | December 31, 2016 | December 31, 2015 |
|---|---|---|
| Cash, cash equivalents and marketable securities | $205.0 million | $108.3 million |
| Working capital | $201.9 million | $109.3 million |
| Total assets | $261.5 million | $181.8 million |
| Long-term debt, net | $199.2 million | $28.0 million |
| Stockholders’ equity (deficit) | $(32.5) million | $43.0 million |
Cash and marketable securities increased following financing, while operating cash use worsened by $13.3 million. Financing activities provided $150.6 million in 2016; investing activities used $76.8 million, mainly reflecting purchases of marketable securities. Management said available cash and expected collaboration revenue should fund operations for at least the next 12 months, but also warned that additional capital would likely be needed in the future and might not be available on favorable terms.
Material developments and outlook
- PEGPH20 in pancreatic cancer: In January 2017, Halozyme reported interim/topline analyses of Phase 2 Study 109-202. In the combined Stage 1 and Stage 2 HA-High population, median progression-free survival (PFS) was 9.2 months with PEGPH20 plus nab-paclitaxel and gemcitabine versus 5.2 months with chemotherapy alone (HR 0.51; p=0.048). In the overall efficacy-evaluable population, median PFS was 6.0 versus 5.3 months (HR 0.73; p=0.048). These analyses were based on a December 2016 cutoff; the database remained open and the filing said an updated analysis and final report would follow.
- In Stage 2 HA-High patients, median PFS was 8.6 versus 4.5 months and median overall survival was 11.7 versus 7.8 months; the reported confidence intervals were wide. The study’s safety endpoint was met: thromboembolic-event rates in the PEGPH20 arm fell from 43% in Stage 1 to 10% in Stage 2, following exclusion of higher-risk patients and anticoagulant prophylaxis. In the combined analysis, exploratory median overall survival was 11.5 versus 8.5 months; the filing noted possible imbalances and treatment interruption as factors affecting interpretation.
- Phase 3 Study 109-301 began dosing in March 2016, testing PEGPH20 plus chemotherapy in HA-High stage IV pancreatic cancer, with PFS and overall survival endpoints. By January 2017, 85% of global sites had been initiated. FDA marketing approval would depend on the overall benefit-risk assessment, including efficacy, toxicity and overall-survival data. PEGPH20 had FDA Fast Track and orphan-drug designations and EU orphan designation; these do not assure approval.
- Other PEGPH20 programs included a Phase 1b study with pembrolizumab in lung and gastric cancers and a Phase 1b/2 study with eribulin in metastatic breast cancer. The company discontinued its PRIMAL lung-cancer study in August 2016. Genentech and Halozyme agreed to clinical studies combining PEGPH20 with Tecentriq, planned to begin in 2017.
- Partner developments were mixed: Janssen reported Phase 1b results supporting continued daratumumab/rHuPH20 development and planned a Phase 3 study. Pfizer discontinued programs involving bococizumab and rivipansel, and returned the PCSK9 target; AbbVie discontinued its HUMIRA/rHuPH20 program after Phase 1 results did not meet target results. Roche’s U.S. rituximab SC BLA was accepted for review.
- Halozyme’s stated outlook included expected higher PEGPH20 R&D spending as development advanced, moderately higher SG&A, and potentially lower Roche-related R&D reimbursement in 2017 as manufacturing-facility validation was expected to conclude. Management expected bulk supply revenue to fluctuate and Hylenex sales to be flat or grow modestly; royalty revenue was generally expected to rise with partner product sales, subject to variation.
Debt, risks and contingencies
In January 2016, a subsidiary borrowed $150 million secured by Roche and Baxalta royalty streams. The loan bears interest at 8.75% plus three-month LIBOR, subject to a 0.7% floor and 1.5% cap; its year-end rate was 9.71%. The reported balance was $161.8 million, including $13.2 million of capitalized payment-in-kind interest. Halozyme expected repayment in the first quarter of 2020, but timing depends on royalties and could extend. In June 2016, the company drew $55 million under a new Oxford/Silicon Valley Bank facility, with an option for another $15 million in the second quarter of 2017; the year-end balance was $54.8 million. The company reported compliance with material loan covenants at year-end. Debt covenants, collateral provisions and potential acceleration on default could constrain operations and liquidity.
- Clinical and regulatory risk remains substantial. PEGPH20 previously faced a clinical hold over a possible excess of thromboembolic events; the program resumed under a revised protocol with risk exclusions and anticoagulant prophylaxis. Safety, efficacy, trial execution and companion-diagnostic performance remain key uncertainties.
- Revenue is concentrated: Roche represented 63% of 2016 revenue, and Baxalta 12%. Accounts receivable were also concentrated, with approximately 81% due from Roche and Baxalta.
- The business relies on external manufacturers for rHuPH20, PEGPH20 and product finishing, as well as on collaborators for development and commercialization. Supply interruption or a partner’s withdrawal could delay programs or reduce revenue.
- Halozyme had no history of profitability, significant continuing cash requirements, and a risk of future financing-related dilution or restrictive borrowing terms. It reported no material pending legal proceeding and no material off-balance-sheet arrangements.
- The company noted a planned 2018 adoption of the new revenue-recognition standard and anticipated a material financial-statement impact, including possible changes in timing of collaboration/license revenue and sales-based royalties; the amount was not yet estimable.
Fourth-quarter 2016 snapshot
Unaudited Q4 revenue was $39.0 million, product-sales gross profit was $5.4 million, operating expenses were $61.6 million, and net loss was $27.4 million, or $0.21 per share. The filing does not provide a clear standalone Q4 cash-flow figure.
Most important facts for investors to verify
- Final, locked Study 109-202 results and the statistical and clinical significance of PEGPH20’s PFS and overall-survival effects, especially in the prospectively defined HA-High population.
- Study 109-301 enrollment, timing, efficacy and safety outcomes; thromboembolic and other adverse-event rates; and FDA/EMA benefit-risk requirements.
- Actual partner sales, royalty growth and continued collaboration participation, given Roche’s revenue concentration and discontinued partner programs.
- Cash burn, available liquidity, debt balances and terms, royalty-backed repayment assumptions, and whether the optional $15 million loan tranche was drawn.
- Manufacturing capacity and validation, including third-party supply continuity, and the financial impact of adopting the new revenue-recognition standard.